Literature DB >> 8957012

Human T-cell lymphotropic virus type II-associated myelopathy: clinical and immunologic profiles.

T J Lehky1, N Flerlage, D Katz, S Houff, W H Hall, K Ishii, C Monken, S Dhib-Jalbut, H F McFarland, S Jacobson.   

Abstract

Human T-cell lymphotropic virus type II (HTLV-II) is endemic in several ethnic tribes and among intravenous drug users in metropolitan areas. Despite the presence of HTLV-II in these various populations, the association of HTLV-II with disease is sparse and mainly limited to isolated case reports. This study is an extension of an earlier description of an HTLV-II-infected patient with neurologic disease and presents the clinical and immunologic findings of 4 patients with HTLV-II seropositivity and spastic paraparesis. The patients are of African-American origin with 3 of the patients being of Amerindian descent. All of the patients are seronegative for the human immunodeficiency virus (HIV). The patients progressed to a nonambulatory state in less than 5 years. Magnetic resonance imaging studies obtained from 3 of the patients demonstrated white matter disease in the cerebrum and spinal cord. The cerebrospinal fluid and serum contained antibodies to HTLV-II. The presence of proviral HTLV-II was confirmed by polymerase chain reaction analysis of peripheral blood lymphocytes (PBLs). A spinal cord biopsy from 1 patient demonstrated HTLV RNA within a lesion. Immunologic studies on 2 patients demonstrated that spontaneous lymphoproliferation of PBLs was present but decreased relative to HTLV-I-infected patients. The clinical and immunologic findings from these HTLV-II-infected patient resemble those found in HTLV-I-associated myelopathy/tropical spastic paraparesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8957012     DOI: 10.1002/ana.410400507

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  10 in total

1.  Major histocompatibility complex class II transactivator CIITA is a viral restriction factor that targets human T-cell lymphotropic virus type 1 Tax-1 function and inhibits viral replication.

Authors:  Giovanna Tosi; Greta Forlani; Vibeke Andresen; Marco Turci; Umberto Bertazzoni; Genoveffa Franchini; Guido Poli; Roberto S Accolla
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

2.  HUMAN T-LYMPHOTROPIC VIRUS 1 (HTLV-1) AND HUMAN T-LYMPHOTROPIC VIRUS 2 (HTLV-2): GEOGRAPHICAL RESEARCH TRENDS AND COLLABORATION NETWORKS (1989-2012).

Authors:  Gregorio González-Alcaide; José Manuel Ramos; Charles Huamaní; Carmen de Mendoza; Vicent Soriano
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2016-02-23       Impact factor: 1.846

3.  Human T-lymphotropic virus type 2 subtype b in a patient with chronic neurological disorder.

Authors:  Carolina Rosadas; Ana C P Vicente; Louise Zanella; Mauro J Cabral-Castro; José M Peralta; Marzia Puccioni-Sohler
Journal:  J Neurovirol       Date:  2014-09-03       Impact factor: 2.643

Review 4.  Human T-cell lymphotropic virus type I and neurological diseases.

Authors:  Masahiro Nagai; Mitsuhiro Osame
Journal:  J Neurovirol       Date:  2003-04       Impact factor: 2.643

5.  Inhibition of human T cell leukemia virus type 2 replication by the suppressive action of class II transactivator and nuclear factor Y.

Authors:  Giovanna Tosi; Elisabetta Pilotti; Lorenzo Mortara; Andrea De Lerma Barbaro; Claudio Casoli; Roberto S Accolla
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-14       Impact factor: 11.205

6.  Proinflammatory cytokine gene induction by human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 Tax in primary human glial cells.

Authors:  Prabal Banerjee; Rosemary Rochford; J Antel; G Canute; Stephen Wrzesinski; Michelle Sieburg; Gerold Feuer
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

Review 7.  Human T-cell lymphotropic virus type 1 and its oncogenesis.

Authors:  Lan-Lan Zhang; Jing-Yun Wei; Long Wang; Shi-le Huang; Ji-Long Chen
Journal:  Acta Pharmacol Sin       Date:  2017-04-10       Impact factor: 6.150

8.  Human T-lymphotropic virus type 2 (HTLV-2) provirus in circulating cells of the monocyte/macrophage lineage in patients dually infected with human immunodeficiency virus type 1 and HTLV-2 and having predominantly sensory polyneuropathy.

Authors:  G Zehender; L Meroni; S Varchetta; C De Maddalena; B Cavalli; M Gianotto; A B Bosisio; C Colasante; G Rizzardini; M Moroni; M Galli
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

9.  Neurologic abnormalities in HTLV-I- and HTLV-II-infected individuals without overt myelopathy.

Authors:  H H Biswas; J W Engstrom; Z Kaidarova; G Garratty; J W Gibble; B H Newman; J W Smith; A Ziman; J L Fridey; R A Sacher; E L Murphy
Journal:  Neurology       Date:  2009-09-08       Impact factor: 9.910

10.  The MHC-II transactivator CIITA, a restriction factor against oncogenic HTLV-1 and HTLV-2 retroviruses: similarities and differences in the inhibition of Tax-1 and Tax-2 viral transactivators.

Authors:  Greta Forlani; Rawan Abdallah; Roberto S Accolla; Giovanna Tosi
Journal:  Front Microbiol       Date:  2013-08-22       Impact factor: 5.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.